ORPHAC logo

Strategic Partners A/SBATS-CHIXE:ORPHAC Stock Report

Market Cap DKK 38.7m
Share Price
n/a
My Fair Value
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Strategic Partners A/S

BATS-CHIXE:ORPHAC Stock Report

Market Cap: DKK 38.7m

Orphazyme (ORPHAC) Stock Overview

Does not have significant operations. More details

ORPHAC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings have grown 29.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (DKK39M)

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (DKK0)


ORPHAC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.1% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.7k
22
2
54
28d ago

Orphazyme A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Orphazyme
Historical stock prices
Current Share PriceDKK 911.50
52 Week HighDKK 0
52 Week LowDKK 0
Beta0.14
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-98.16%

Recent News & Updates

Recent updates

Shareholder Returns

ORPHACGB BiotechsGB Market
7D0%-5.3%-0.9%
1Yn/a16.2%21.7%

Return vs Industry: Insufficient data to determine how ORPHAC performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how ORPHAC performed against the UK Market.

Price Volatility

Is ORPHAC's price volatile compared to industry and market?
ORPHAC volatility
ORPHAC Average Weekly Movementn/a
Biotechs Industry Average Movement9.9%
Market Average Movement5.6%
10% most volatile stocks in GB Market11.4%
10% least volatile stocks in GB Market3.2%

Stable Share Price: ORPHAC has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ORPHAC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091Jakob Bendtsenwww.strategic-partners.dk

Orphazyme A/S does not have significant operations. Previously, it was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is based in Herlev, Denmark.

Orphazyme A/S Fundamentals Summary

How do Orphazyme's earnings and revenue compare to its market cap?
ORPHAC fundamental statistics
Market capDKK 38.67m
Earnings (TTM)-DKK 26.05m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.5x
P/E Ratio

Is ORPHAC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORPHAC income statement (TTM)
RevenueDKK 0
Cost of RevenueDKK 0
Gross ProfitDKK 0
Other ExpensesDKK 26.05m
Earnings-DKK 26.05m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-737.65
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ORPHAC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/08 06:07
End of Day Share Price 2024/02/09 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Strategic Partners A/S is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Jacob LademannCarnegie Investment Bank AB
Thomas BowersDanske Bank